Promising drug trial for rare pancreatic cancer stopped early
NCT ID NCT06158516
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug surufatinib could help prevent pancreatic neuroendocrine tumors from coming back after surgery. The trial was planned for many participants but was stopped early with only 6 people enrolled. Because it ended early, we don't have clear answers on whether the drug works better than a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changhai Hospital
Shanghai, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do Younger-Age pancreatic tumors behave differently? a new study digs in
- One dose may not fit all: blood tests could tailor cancer drug dosing
- New risk score aims to predict which pancreatic tumors will return after surgery
- Zapping pancreatic tumors without surgery: a safer approach?
- Could chemo after surgery stop pancreatic tumor return?
- New PET scan agent aims to better detect rare tumors